A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
Clinical trial NCT05274997 · UNKNOWN
Trial details
- NCT number
- NCT05274997
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-01
- Primary completion
- 2023-01-01
- Enrollment
- 97
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.